After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...